Track topics on Twitter Track topics that are important to you
Myriad Genetics, through its Assurex Health subsidiary, said today it will partner with the U.S. Department of Veterans Affairs to assess the company's GeneSight ® genetic test in veterans diagnosed with major depressive disorder (MDD). GeneSight will be evaluated in the PRIME Care (PRecision Medicine In MEntal Health Care) study, a randomized clinical trial designed to show the effectiveness of providing veterans suffering from depression, and their providers, the results of pharmacogenomic testing for psychotropic medications via GeneSight ( NCT03170362 ). The study is designed to show whether and how patients and providers use genetic test results given to them at the time an antidepressant is to be initiated to treat MDD, and whether use of the test results improves patient outcomes. According to the VA, approximately 20% of the 2.6 million veterans who deployed to Iraq or Afghanistan as part of the nation’s War on Terror ...
Original Article: Myriad Genetics, VA to Assess Genetic Test for Major Depressive DisorderNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Psychiatry is the study of mental disorders and their diagnosis, management and prevention. Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...